Table 6 Common differentially methylated CpGs in breast and prostate cancers identified using overlap analyses.

From: Integrative multi-omic analysis identifies genetically influenced DNA methylation biomarkers for breast and prostate cancers

CpG

CHR

Location (bp)

Cytoband

Gene

BrCa+PrCa i-MeWAS Z score

BrCa i-MeWAS Z score

PrCa i-MeWAS Z score

BrCa TN-DM Z score

PrCa TN-DM Z score

cg07421287*

1

111218287

1p13.3

KCNA3

3.14

0.71

4.17

−4.97

−5.83

cg24789467*#

5

132159003

5q31.1

SHROOM1

−4.29

−2.99

−3.15

−4.13

−3.73

cg09205595*#

7

150782539

7q36.1

AGAP3

3.51

2.96

1.91

3.75

4.12

cg26405020#

15

91427363

15q26.1

FES, FURIN

−5.10

−4.03

−3.14

3.23

3.71

cg14918082*

17

7833237

17p13.1

KCNAB3, TRAPPC1

−3.73

−2.14

−3.30

−5.02

−4.78

cg08129017

17

17728660

17p11.2

SREBF1

5.64

3.58

4.58

5.20

3.29

cg20513976*

20

62367893

20q13.33

LIME1

−3.97

0.84

−7.71

−2.93

−5.21

cg12413156*

20

62368256

20q13.33

LIME1

−3.82

1.40

−8.20

−3.30

−3.74

  1. BrCa breast cancer, PrCa prostate cancer, i-MeWAS imputation-based methylome-wide association study, TN-DM tumour vs normal tissue adjacent to tumour differential methylation.
  2. *and #indicate that the CpGs that were not significantly differentially methylated in BrCa i-MeWAS analysis (FDR > 0.05) PrCa i-MeWAS analysis (FDR > 0.05), respectively. The row in bold font indicates the common DM CpG between the eight DM CpGs identified through the overlap analysis using BrCa+PrCa meta-analysed GWAS-SS (Fig. 4a) and the one DM CpG identified through the overlap analysis of individual GWAS-SS (Fig. 4b).
Back to article page